A -year-old man comes to the office to discuss screening for Alzheimer disease. He recently read about a new plasma biomarker test that was approved for clinical use. The physician explains that this test was evaluated in a specialized memory disorders clinic where the prevalence of Alzheimer disease is . In that setting, the test had a sensitivity of and a specificity of . The physician is considering using this test for asymptomatic patients in the primary care setting, where the prevalence of Alzheimer disease is estimated to be . Which of the following best describes the expected change in the test's positive predictive value (PPV) and negative predictive value (NPV) when applied in this general practice setting compared to the specialized clinic?
- PPV will decrease, and NPV will increaseCevap
- BPPV will increase, and NPV will decrease
- CBoth PPV and NPV will remain unchanged
- DPPV will decrease, and NPV will remain unchanged
- EPPV will remain unchanged, and NPV will increase